Re: [MOL] CPT11

["Lillian" <firefly@islc.net>]

Hi and welcome to our wonderful forum.  I have attatched a site for you to
explore and I will keep chicking for other sites for you.  Good luck, your
friend, lillian
Medscape   Home   Site Map   Marketplace   My Medscape   CME Center
Feedback   Help Desk





Search for "(Chemotherapy)" in Medscape's free Full-Text Articles or the
Medscape Bookstore



Title
A risk model for thrombocytopenia requiring platelet transfusion after
cytotoxic chemotherapy.
Author
Blay JY; Le Cesne A; Mermet C; Maugard C; Ravaud A; Chevreau C; Sebban C;
Guastalla J; Biron P; Ray-Coquard I
Address
Centre L. B´erard, Lyon, France. blay@lyon.fnclcc.fr
Source
Blood, 92(2):405-10 1998 Jul 15
Abstract
Severe thrombocytopenia is a rare but life-threatening side effect of
cytotoxic chemotherapy for which risk factors are not well known. Our
objective was to delineate a risk model for chemotherapy-induced
thrombocytopenia requiring platelet transfusions in cancer patients.
Univariate and multivariate analysis of risk factors for
chemotherapy-induced thrombocytopenia requiring platelet transfusions were
performed on the cohort of the 1,051 patients (CLB 1996) treated with
chemotherapy in the Department of Medicine of the Centre L´eon B´erard (CLB)
in 1996. In univariate analysis, performance status (PS) greater than 1,
platelet count less than 150, 000/microL at day 1 (d1) before the initiation
of chemotherapy, d1 lymphocyte count < or = 700/microL, d1 polymorphonuclear
leukocyte count less than 1,500/microL, and the type of chemotherapy (high
risk v others) were significantly associated (P < .01) with an increased
risk of severe thrombocytopenia requiring platelet transfusions. Using
logistic regression, d1 platelet count less than 150,000/microL (odds ratio
[OR], 4.3; 95% confidence interval [CI], 1.9 to 9.6), d1 lymphocyte counts <
or = 700/microL (OR, 3.37; 95% CI, 1.77 to 6.4), the type of chemotherapy
(OR, 3.38; 95% CI, 1.77 to 6.4), and PS greater than 1 (OR, 2.23; 95% CI,
1.22 to 4.1) were identified as independent risk factors for platelet
transfusions. The observed incidences of platelet transfusions were 45%,
13%, 7%, and 1.5% for patients with > or = 3, 2, 1, or 0 risk factors,
respectively. This model was then tested in 3 groups of patients treated
with chemotherapy used as validation samples: (1) the series of 340 patients
treated in the CLB in the first 6 months of 1997, (2) the prospective
multicentric cohort of 321 patients of the ELYPSE 1 study, and (3) the
series of 149 patients with non-Hodgkin's lymphoma treated in the CLB within
prospective phase III trials (1987 to 1995). In these 3 groups, the observed
incidences of platelet transfusions in the above-defined risk groups did not
differ significantly (P > .1) from those calculated in the model. This risk
index could be useful to identify patients at high risk for
chemotherapy-induced thrombocytopenia requiring platelet transfusions.
Language
Eng
Unique Identifier
98322144


----------------------------------------------------------------------------
----


MESH Headings
Adult ; Aged ; Antineoplastic Agents, Combined *AE/TU ; Female ; Human ;
Male ; Middle Age ; Neoplasms *DT ; Platelet Transfusion * ; Regression
Analysis ; Risk ; Risk Factors ; Support, Non-U.S. Gov't ; Thrombocytopenia
*CI/*TH


----------------------------------------------------------------------------
----


Publication Type
JOURNAL ARTICLE
ISSN
0006-4971
Country of Publication
UNITED STATES
CAS Registry Number
0 (Antineoplastic Agents, Combined)

  Home   Site Map   Marketplace   My Medscape   CME Center   Feedback   Help
Desk


 Medscape Search Options
Medscape Full-Text
News
Info for Patients
MEDLINE
AIDSLINE
TOXLINE
Drug Info
Bookstore
Dictionary
Whole Web

Select a database to search, enter a search term, then click “go.”



All material on this website is protected by copyright. Copyright ©
1994-1999 by Medscape Inc. All rights reserved. This website also contains
material copyrighted by 3rd parties. CME means Continuing Medical Education
credit is available. Medscape requires 3.x browsers or better from Netscape
or Microsoft.
-

----Original Message-----
From: Vgricks@AOL.COM <Vgricks@AOL.COM>
To: mol-cancer@lists.meds.com <mol-cancer@lists.meds.com>
Date: Friday, May 28, 1999 10:04 AM
Subject: [MOL] CPT11


>I am interested in any info on CPT11.  I have colorectal cancer with spread
>to the lungs.  I have had surgery to remove tumors from the lungs and now
am
>interested to find out if CPT11 would help.
>------------------------------------------------------------------------
>This is an automatically-generated notice.  If you'd like to be removed
>from the mailing list, please visit the Medicine-On-Line Discussion Forum
>at <http://www.meds.com/con_faq.html>, or send an email message to:
>majordomo@lists.meds.com
>with the subject line blank and the body of the message containing the
line:
>unsubscribe mol-cancer your-email-address
>where the phrase your-email-address is replaced with your actual email
>address.
>------------------------------------------------------------------------
>

------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------